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Summary The level of expression ofenzymes that can activate ordetoxify bioreductive agents within tumours has emerged as an important
feature in the development of these anti-tumour compounds. The levels of two such reductase enzymes have been determined in 19 human
non-small-cell lung tumours and 20 human breast tumours, together with the corresponding normal tissue. DT-diaphorase (DTD) enzyme
levels (both expression and activity) were determined in these samples. Cytochrome b5 reductase (Cytb5R) activity was also assessed. With
the exception of six patients, the levels of DTD activity were below 45 nmol min-1 mg-' in the normal tissues assayed. DTD tumouractivity was
extremely variable, distinguishing two different groups of patients, one with DTD activity above 79 nmol min-1 mg-1 and the other with levels
that were in the same range as found for the normal tissues. In 53% of the lung tumour samples, DTD activity was increased with respect to
the normal tissue by a factor of 2.-90.3 (range 79-965 nmol min-1 mg-1). In 70% of the breast tumour samples, DTD activity was over
80 nmol min-1 mg-1 (range 83-267 nmol min-' mg-'). DTD expression measured by Western blot correlated well with the enzyme activity
measured in both tumour and normal tissues. The levels ofthe other reductase enzyme, Cytb5R, were not as variable as those for DTD, being
in the same range in both tumour and normal tissue or slightly higher in the normal tissues. The heterogeneous nature of DTD activity and
expression reinforces the need to measure enzyme levels in individual patients before therapy with DTD-activated bioreductive drugs.
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It has been proposed that the low oxygen levels of solid tumours,
caused by insufficient vascularization, could be conducive to the
reductive metabolism ofa prodrug within the tumour to generate a
compound more toxic than the parent compound (Sartorelli,
1988). The biochemical basis for such a desirable therapeutic
selectivity is believed to involve the ability ofmolecular oxygen to
reverse the reductive bioactivation process that results in the
generation ofthe ultimate cellcytotoxin, usually aDNA alkylating
agent or, in the case of N-oxides, a hydrogen-abstracting radical
(Kennedy et al, 1980; Workman, 1992; Workman and Stratford,
1993). A number of promising bioreductive agents are at various
stages ofdevelopment. Both the indoloquinone E09 (a mitomycin
C derivative) and the N-oxide SR4233 are currently undergoing
phase I and II clinical evaluation (Doherty et al, 1994; Schellens et
al, 1994; Robinson and Castanier, 1995).
However, the selectivity of bioreductive agents may be
governed not only by the difference in oxygen content of tumour
vs normal tissues, but also by the level of expression of enzymes
catalysing the reductive activation process (Workman and Walton,
1990; Workman, 1994). A numberofenzymes havebeen shown to
reduce bioreductive compounds both in vitro and in vivo,
including the one-electron reducing enzymes, cytochrome P450
(several isoenzymes), NADPH cytochrome P450 reductase,
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NADH cytochrome b5 reductase, and the two-electron reducing
enzyme, DT-diaphorase. Other reductases, such as xanthine
oxidase/dehydrogenase, carbonyl reductase and aldehyde oxidase,
may also play a part.
Much ofthe attention has focused on the enzyme DT-diaphorase
(DTD, EC 1.6.99.2), because it is considered to be the most impor-
tant enzyme for the bioreductive activation of several quinone-
based anti-cancer drugs, such as mitomycin C and E09. DTD is
present in many mammalian tissues where it can play a role in the
biosynthesis of vitamin K (Suttle, 1985), or may act as a detoxi-
fying enzyme for simple quinone-containing compounds by
catalysing a strict two-electron reduction (lyanagi and Yamazaki,
1969). Quinones are widely distributed in nature and can produce
mutagenicity, carcinogenicity and cell necrosis in mammalian
cells (Nohl et al, 1986; Sies, 1986). One-electron enzymatic reduc-
tion is thought to be the major mechanism responsible for the
toxicity ofquinones. This reduction (reversible in the presence of
oxygen) leads to a semiquinone radical and to the formation ofthe
highly toxic alkylating species (Tomasz et al, 1987). Two-electron
enzymatic reduction of quinones gives rise to hydroquinones,
traditionally considered to be less reactive than semiquinone radi-
cals and more easily eliminated from the cell as conjugates (Lind,
1985). DTD has been reported as an anti-mutagenic and anti-
carcinogenic enzyme in this context Chesis et al, 1984; Prochaska
et al, 1987; Belinsky and Jaiswal, 1993).
Thepotential role forDTD in cancerchemotherapy is as an acti-
vator of bioreductive prodrugs, under both aerobic and hypoxic
conditions. Plumb et al (1994a) found a positive correlation
between DTD activity and the aerobic sensitivity to the quinone
E09 in a large panel of human cancer cell lines. Several reports
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Table 1 Characteristics of lung tumour patients
Patient Tobacco usea Histological typeb Gradec TNM Stage
1 S AD G2 T2NOMO
2 PS EC G2 T2N1MO II
3 PS AD G3 T2N1MO II
4 PS AD Gl T1NOMO
5 S AD' G2 T4N1MO IIIB
6 S AD ? TlNOMO
7 PS EC G3 T4NOMO IIIB
8 PS EC G1 T2NOMO
9 NS AD Gl TlNOMO
10 PS EC G1 T2NOMO IIIA
11 S AD2 ? T2NOMO
12 NS Carcinoid G2 TlNOMO
13 PS EC G3 TlNOMO
14 S EC G2 T3NOMO IIIA
15 PS MC G3 T2NOMO
16 PS EC G2 T3N2M1 IV
17 ? EC G3 T3NOMO IIIA
18 PS EC G2 T3N2MO IIIA
19 PS EC or LCC G2 T4N3MO IIIB
aTobacco use: S, smokers; PS, past-smokers; NS, non-smokers. Groups made as described by others (Schlager
and Powis, 1990). bHistological type: AD, adenocarcinoma; AD', possible mixed oatcell/epidermoid carcinoma;
AD2, recurrence; EC, epidermoid carcinoma; MC, mucoepidermoid carcinoma; LCC, large-cell carcinoma.
cGrade: Gl, well-differentiated; G2, moderately differentiated; G3, poorly differentiated. ?, not registered.
have shown there to be higher DTD levels (both activity and
mRNA) in tumour cells when compared with normal tissues
(Schor and Cornelisse, 1983; Cresteil and Jaiswal, 1991;
Smitskamp-Wilms et al, 1995; Fitzsimmons et al, 1996), although
not for all tumour types (Schlager and Powis, 1990). This has
given rise to the suggestion that drugs activated by DTD could be
selectively toxic to certain types oftumour.
While hypoxia is thought to be a phenomenon restricted to
poorly vascularized tumours, DTD is widely distributed
throughout the body, and high levels are observed in the kidney
and intestine (Ermster, 1967), suggesting that these tissues may be
sensitive to the aerobic toxicity of bioreductive agents such as
E09. Indeed, the dose-limiting toxicity of E09 is proteinuria
(Schellens et al, 1994), possibly indicative of damage to the
kidney following DTD activation in this enzyme-rich organ, while
the absence of myelosuppression is consistent with the very low
levels ofthis enzyme in the bone marrow (Lewis et al, 1993).
The activity corresponding to the one-electron-reducing enzyme
cytochrome b5 reductase (Cytb5R, EC 1.6.2.2), which uses NADH
as a cofactor, rises slightly at low pHs (like those developed in
hypoxic areas of tumours) and can reduce other quinone-based
compounds such as mitomycin C, producing the semiquinone
radical under hypoxic conditions (Hodnick and Sartorelli, 1993).
Cytb5R is a promising enzyme but its levels in human tumour
tissues are not known.
If enzyme-directed bioreductive agents are to have a place in
cancer therapy, it is essential that the levels of reductases in both
tumours and normal tissues are known. Therefore, in this work we
have measured DTD in two different ways, by activity and protein
expression, in anumberofpairedhumanlung andbreastnormal and
tumour tissues. The variability ofDTD is analysed and the possible
implications discussed. The activity of the one-electron reducing
enzyme, Cytb5R, was measured for comparison and because of its
possible role in the selective activation ofbioreductive drugs under
hypoxia (Plumb et al, 1994b; Robertson et al, 1994).
MATERIALS AND METHODS
Patient characteristics
Biopsy specimens of 19 lung solid tumours and 20 breast tumours
were obtained from two hospitals in Pamplona, Spain. Primary
solid tumours were obtained together with macroscopically
normal tissue from the same subject. Full medical records were
kept for all the subjects in the study. Records were not collected
until after the tissues had been analysed for reductase levels. The
following data were obtained: age, sex, ethnic origin, current
pathologies and medication, tobacco use, tumour histology and
grade, presence ofmetastasis and the tumour staging according to
the TNM classification status (AJCC, 1992). Patient characteris-
tics are briefly described in Tables 1 and 2.
The mean age of the patients with lung tumours was 65 years.
All of them were smokers or ex-smokers except for the two
women in the study, who had no recorded tobacco product use. In
general, they were receiving concomitant medication for non-
malignant pathologies, such as cardiac and/or respiratory patholo-
gies. Previous malignant pathologies had occurred in six cases
(patients 9, 15, 13, 17, 19 and 11); forthe last three this was also in
the lungs. Three patients had prior chemotherapy: patient 5 with
cisplatin, vinorelbine and taxol; patient 18 with cisplatin, carbo-
platin and mitomycin C; and patient 19 with cisplatin, vinorelbine
and mitomycin C. Patient 9 took tamoxifen during the last month
before the operation because she suffered a parallel breast
carcinoma. The tumour histological type, grade, TNM status and
staging appear in Table 1.
The mean age of the patients with breast tumours was 51 years.
All were females undergoing radical or conservative surgery.
Previous malignant pathologies occurred in six cases (patients 1,
11, 16, 4, 14 and 19), in the breast in the last three cases. Non-
malignant breast pathologies were suffered in two cases (patients 6
and 13). Patient4 was undergoing hormone therapy withtamoxifen
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Table 2 Characteristics of breast tumour patients
Patient HRa Histological typeb Gradec TNMd Stagee
1 ER(+)PR(+) DIC* G3 T2NOMO IIA
2 ER(+)PR(+) LIC G2 T2NOMO IIB
3 ER(-)PR(+) DC Gl T2NOMO IIA
4 ER(-)PR(-) LIC G3 T4N2MO IIIB
5 ER(+)PR(-) DIC G2 Ti NOMO
6 ER(-)PR(+) DIC G3 TlNOMO
7 ER(+)PR(+) DIC G3 T2N1 MO IIB
8 ER(-)PR(-) DIC* G2 T2NOMO IIA
9 ER(+)PR(+) CA Gl TlNOMO
10 ER(-)PR(+) MixedC* G2 T3N1MO IIIA
11 ER(+)PR(-) DIC Gl TlNlMO IIA
12 ER(-)PR(+) DIC* G2 TlNOMO I
13 ER(+)PR(+) DIC G3 T2NOMO IIA
14 ER(+)PR(+) DIC* G3 Tl NlMO IIA
15 ER(+)PR(+) DIC G3 T2NOMO IIA
16 ER(+)PR(-) IC G2 T2N1M1 IV
17 ER(-)PR(-) DIC* G3 T2N1MO IIB
18 ER(+)PR(-) DIC G3 T2NOMO IIA
19 ER(+)PR(-) MixedC G2 T2NOMO IIA
20 ? DIC G2 T4N1M1 IV
aHR: tumour presence (+) or absence (-) of the oestrogen (ER) or progesterone (PR) receptors. ?, not registered.
bHistological type: DIC, ductal infiltrating carcinoma; LIC, lobular infiltrating carcinoma; DC, in situ ductal carcinoma; CA,
colloid adenocarcinoma; MixedC, mixed ductal and lobular infiltrating carcinoma; Cl, intraductal carcinoma. *Although this
was the most prevailing histological type in these samples, they presented areas or focus where other histological types
were represented. cGrade: Gl, well-differentiated; G2, moderately differentiated; G3, poorly differentiated. dTNM
classification and estage according to AJCC (1992).
because her pathology was a recurrence from a previous breast
carcinoma. Although other patients received chemotherapy, only
patient 20 was given it during the months before surgery (four
cycles ofcyclophosphamide, doxorubicin and 5-fluorouracil).
Tissues
Tissues were obtained from the pathology laboratory. They were
frozen in liquid nitrogen after arrival from the operating theatre
immediately after operation, and kept at-80°C until transported in
liquid nitrogen to the research laboratory, where they were stored
at-I35°C until processed. Tumour and normal tissues were frozen
and stored separately. Batches ofthree or four paired tissues were
processed for enzyme assays at the same time. A piece of liver
from a rat, which had been previously frozen and stored in the
same way as the human tissues, was introduced for processing
with each batch.
The frozen tissues were pulverized with liquid nitrogen in a
porcelain mortar. The powder was weighed and resuspended by
several strokes of a hand-held glass homogenizer, in 3 volumes of
ice-cold homogenizing buffer (potassium phosphate/potassium
chloride 10 mM/0.I M, pH = 7.8, 0.1 mm EDTA, 2 mM phenyl-
methyl sulphonyl fluoride (PMSF) and 80 mg 1-1 trypsin inhibitor).
Finally, the samples were homogenized using an Ultra Turrax-T25
homogenizer (Janke & Kunkel, IKA-labortechnik) or a Potter
homogenizer (B Brown). The temperature was maintained at 4°C
throughout by working on ice. The homogenate was then
centrifuged at 4°C, at 15 000 g for 20 min. The S9 fraction of the
tissues was obtained in the supernatants. These supernatants were
then aliquoted and stored at -80°C until used for enzyme activity
measurements or for Western blot experiments. Reproducibility
was tested with the rat liver samples. Inter- and intra-assay variation
was about 10%. Protein concentration of the supernatants was
determined by the bicinchoninic acid assay (Smith et al, 1985).
Enzyme assays
DTD activity was determined spectrophotometrically by following
the reduction ofcytochrome c at 550 nm, using a modification of
the Ernster method (Ernster, 1967), as reported in detail elsewhere
(Riley and Workman, 1992). Essentially, the reactive mixture
contained cytochrome c (77 im), bovine serum albumin (BSA)
(0.14%, w/v), NADH (0.2 mM) as the cofactor and menadione
(20 ,UM) as the intermediate electron acceptor. The reaction was
initiated with the addition of 10gl ofthe S9 fraction ofthe tissues.
Reactions were conducted at 37°C in a total volume of 1 ml
of Tris-HCl buffer 50 mm (pH 7.4), in the presence and absence
of the specific inhibitor dicoumarol (10jiM). DTD activity was
expressed as the fraction ofactivity measured that was dicoumarol
inhibitable. Cytochrome b5 reductase activity was calculated as the
cytochrome reductase activity measured with NADH (0.2 mM) as
the cofactor, in the absence of a substrate. Both activities were
expressed as nmol cytochrome c (c 21.1 x 103 M cm-1) reduced
min-m mg-1 protein.
DTD expression
The level ofexpression of DTD in S9 tissue fractions (50 ,ug, total
protein) was measured by Western blot analysis after sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE),
using 12% polyacrylamide gels (Laemmli, 1970). Resolved proteins
were electrotransferred to Immobilon-P membranes in transfer
buffer(Tris 48 mM, glycine 39 mM, SDS 0.037% p/v, methanol 10%
v/v). The blots were probed with a primary polyclonal antibody
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Table 3 Reductase activities in human normal and tumour lung tissuesa
DT-diaphorase Cytochrome b5 Reductase
Patient Normal Tumour T/Nb SC Normal Tumour TINb
1 184.1 ± 19.3 114.0 ± 4.7 0.6 21.3/20.1 174.5 ± 2.0 22.5 ± 1.0 0.1
2 7.9 ± 1.0 96.2 ± 4.9 12.2 4.2/nd 40.5 ± 0.3 30.5 ± 0.8 0.7
3 20.6 ±2.2 176.4±3.3 8.5 82.5/nd 76.1 ± 0.6 51.7 ± 0.0 0.7
4 7.9 ± 1.5 127.1 ± 6.0 16.0 24.6/nd 49.4± 1.8 56.2± 1.2 1.1
5 ND 79.0 ± 3.9 79.0(+) 12.4/nd 25.8 ± 0.0 30.3 ± 1.6 1.2
6 26.5 + 0.2 183.2 ± 3.5 6.9 46.7/4.7 39.9 ± 0.8 45.5(*) 1.1
7 37.9 ± 1.7 92.5 ± 1.8 2.4 8.6/5.3 20.2 ± 0.5 21.7 ± 0.0 1.1
8 20.9 ± 1.0 232.6 ± 8.4 11.1 57.1/nd 63.0 ± 1.0 11.6 ±0.0 0.2
9 10.7+0.4 965.8+10.1 90.3 11.4/nd 35.2+0.4 30.1 ±0.4 0.8
10 19.8 + 0.2 434.3 ± 22.9 21.9 76.4/nd 2.7 ± 0.4 17.2 ± 1.6 6.3
11 6.5 ± 0.3 101.6 ± 3.3 15.7 0.6/nd 3.8 ± 0.2 41.5± 1.4 11.0
12 39.1 + 1.6 32.4 ± 1.8 0.8 nd/nd 64.7 +0.9 41.1 ± 0.1 0.6
13 20.0 + 2.6 19.6 ± 1.0 1.0 nd/nd 54.8 ± 7.2 32.9 ± 0.3 0.6
14 5.2 ± 1.9 13.0 ± 2.2 2.5 nd/nd 64.5 ± 1.1 46.1 ±0.1 0.7
15 12.3 ±0.6 1.8 ± 0.2 0.1 nd/nd 64.2 ± 1.9 3.7+ 0.3 0.0
16 2.8 ± 0.4 1.0 ± 0.3 0.3 nd/1.5 29.6 ± 1.3 25.6 ± 1.3 0.9
17 ND 1.1 ± 0.4 1.1(+) nd/nd 15.9 ± 0.4 9.3± 0.1 0.6
18 6.1 ±2.2 1.3±0.1 0.2 nd/nd 84.0±0.1 22.4±0.2 0.3
19 3.3+0.0 4.2±0.6 1.3 nd/nd 25.7±0.1 38.1 ± 1.8 1.5
aDT-diaphorase and Cytb5R activities were measured in the S9 fractions from paired human lung tumour and normal tissue, as described in the text. Reduction
rates are mean ± s.e.m. of three assays of a given homogenate, expressed in nmol cytochrome c reduced min-1 mg-' protein. (*), Only one experiment could be
carried out. bT/N, ratio between tumour and normal tissue activity. ND, not detectable, activity below 1 nmol min-1 mg-1 protein. (+), it is only an estimation
because N is not known. cS, results of the densitometric scans in tumour sample/normal sample. nd, not detected.
raised against purified rat DTD, and developed with a protein
A-horseradish peroxidase conjugate and the chemical reagents of
an enhanced chemoluminescence commercial kit (Amersham).
Films were exposed for no more than 20 min. The optical density
x mm of the bands was determined by scanning densitometry
(Image Master ID, Pharmacia Biotech). The results were normal-
ized with an internal control (cell extracts from a human lung
tumour cell line: HTB-54), and afterward expressed as a
percentage.
Statistical analysis
The Mann-Whitney U-rank sum test was used for assessing differ-
ences between tumour and normal tissues and between tumour
tissues from different patients. Correlation between DTD activity
and DTD protein expression was determined by the non-
parametric Spearman correlation test. A probability of P < 0.05
was considered significant in all cases.
RESULTS
The histological type of the lung tumours analysed are presented
in Table 1. All were non-small-cell lung cancers (NSCLC): ten
epidermoid carcinomas, seven adenocarcinomas, one mucoepider-
moid carcinoma and one carcinoid tumour. The distribution of
cytosolic DTD activities in the tumour and paired normal tissue of
each patient is shown in Table 3. We found low values for this
enzyme in almost all samples ofnormal tissue assayed. The excep-
tion was patient 1, in whose normal tissue we also found an
elevated value for Cytb5R activity. Excluding this value, the
normal lung activity ranged between 0 and 39 nmol min-m mg-'
protein (mean 15.59 ± 2.63). For the tumour tissue, we could
distinguish two different groups: in patients 1-11, DTD was high,
ranging between 79 and 965 nmol min-1 mg-1 protein and, with the
exception of patient 1, it was increased with respect to the normal
tissue (P < 0.001) by a factor of 2.4-90.3. In patients 12-19,
tumour DTD activity was as low as in the normal tissue.
We investigated the heterogeneity in enzyme activity, analysing
the influence ofdifferent factors in tumour DTD. We could not find
any difference between tumour activity from patients with different
habits of tobacco use or from subjects receiving prophylactic anti-
coagulant therapy (which is believed to inhibit the enzyme). When
we compared tumour DTD activity with the tumour staging and
with histological grade or type, we found significant differences (P
< 0.05) in all cases (data shown in Table 4).
The DTD activity in the 20 different sets ofpaired breast tissues
is presented in Table 5. In 70% of the tumour samples (2-15),
DTD activity was over 80 nmol min-1 mg-1 protein (range 83-
267 nmol min-m mg-1 protein). The remaining 30% of the tumour
samples showed low levels of activity, ranging between 5 and
42 nmol min-' mg-' protein. In the normal tissue, DTD activity
was low in the majority of the samples (6-20) ranging between 2
and 45 nmol min-m mg-' protein. The remaining five samples (1-5)
showed elevated levels of DTD activity ranging between 62 and
342 nmol min-1 mg-' protein. Analysing the paired samples
showed that DTD activity was generally induced in tumours (P <
0.001). The influence of several factors that could account for the
heterogeneity in tumour DTD activity was analysed. We only
found significant differences when we compared tumoral DTD
activity from patients positive or negative for the oestrogen
receptor. DTD activity was higher in tumours that were negative
for this receptor (range 28-267 nmol min-m mg-' protein) than in
tumours that were ER positive (range 34-159 nmol min-m mg-1
protein). No other factors, such as progesterone receptor presence,
tumour stage, grade or histological type, gave a significantcorrela-
tion with DTD activity.
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Table 4 Different factors affecting tumour DTD activity.
Factor DTDa Range nb
Grade G1* 179.8+ 37.3 127-232 2
G2 + G3 48.6± 15.8 0.96-176 13
Stage + Il* 108.5 ± 22.6 1-232 10
IIIA + IIIB 22.4 ± 15.8 1-92 5
Histological type AD* 140.4 ± 14.8 101-183 5
EC 57.2 ± 28.7 0-232 8
aDTD, DT-diaphorase activity (mean ± s.e.m.). Units are nmol min-' mg-' protein. Samples 9
and 10 were excluded from the analysis. bn, Number of individual samples (biopsy
specimen). *Tumour DTD activity significantly higher (P< 0.05). The Mann-Whitney U-test
was used for statistical analysis.
Table 5 Reductase activities in human normal and tumour breast tissuesa
DT-diaphorase Cytochrome b5 reductase
Patient Normal Tumour TINb Sc Normal Tumour T/Nb
1 137.3 ± 8.3 41.8 ± 2.7 0.3 4.3/68.7 69.7 ± O.Oa 42.4 ± 0.2 0.6
2 258.6 ± 1.3 99.0 ± 25.9 0.4 21.5/56.6 24.4 + 0.0 NS -
3 342.4± 1.2 267.3± 11.0 0.8 38.6/41.5 23.1 ±0.1 16.9±0.0 0.7
4 93.1 ±2.6 157.9±5.7 2.5 39.1/0.6 10.9+0.1 9.6±0.7 0.9
5 62.0 ± 9.8 159.5 ± 2.5 2.6 31.9/9.5 10.67* 11.9 ± 0.7 1.1
6 44.7 ± 3.1 130.7 ± 3.8 2.9 11.7/3.1 28.7 ± 0.6 15.9 ± 3.8 0.5
7 6.0 ± 0.7 96.2 ± 4.5 16.0 5.8/1.7 4.8 ± 0.2 17.6 ± 0.4 3.6
8 10.6 ± 1.7 197.7 ± 3.0 18.6 50.4/nd 38.3 ± 0.8 30.7 + 0.9 0.8
9 3.4 ± 0.3 82.9 ± 3.7 24.4 23.5/nd 13.0 + 0.3 19.7 ± 0.6 1.5
10 17.8 ± 0.9 119.5 ±2.4 6.7 53.8/7.9 17.3 ± 0.4 14.9 + 0.3 1.1
11 12.7 ± 1.1 122.9 ± 3.5 9.7 53.5/nd - - -
12 26.4 ± 2.7 177.1 ±1.4 6.7 nd/nd -
13 9.6 ± 0.9 129.8 ± 3.9 13.5 86.5/nd 9.4 ± 0.4 14.9+0.3 1.7
14 23.0 ± 1.1 127.0 ± 5.0 5.5 3.9/nd 11.4 ± 0.9 8.8± 1.3 1.8
15 2.3 ± 0.5 96.9 ± 7.8 42.1 24.2/nd NS 8.9± 0.4 -
16 2.3 ± 0.0 33.9 ± 0.8 14.7 2.7/nd 4.7± 0.3 7.9+ 0.4 1.7
17 11.6±0.4 27.6±1.2 2.4 23.1/0.5 12.1 ±0.4 22.4±0.5 1.8
18 4.4 ± 0.8 34.5 ± 2.0 7.8 3.6/nd 23.2 ± 0.9 15.9 ± 0.7 0.7
19 3.3 ± 0.0 5.3 ± 0.7 1.6 nd/nd 7.23 ± 0.7 4.55* 0.6
20 14.3±1.6 11.2±1.3 0.8 nd/nd 12.6±0.1 7.9±0.7 0.6
aDT-diaphorase and CytbsR activities were measured in the S9 fractions from paired human breast tumour and normal tissue, as described in the text. Reduction
rates are mean ± s.e.m. of three assays of a given homogenate, expressed in nmol cytochrome c reduced mirr' mg-' protein. (*) Only one experiment could be
carried out. bT/N, ratio between tumour and normal tissue activity. cS, results of the densitometric scans in tumour sample/normal sample. nd, not detected.
Figures 1 and 2 show several representative examples of the
Westem blot experiments for determining DTD protein expression
in the samples. The correlation of DTD activity vs DTD expres-
sion measured densitometrically was significant for both tumour
and normal tissue. The results of the densitometric scanning,
expressed as a percentage referred to the intemal control, are
included in Tables 3 and 5. Spearman correlation coefficient was rs
= 0.753*** (P < 0.001) for breast normal tissue and rs = 0.532*
(P < 0.05) for breast tumour tissue; rs = 0.924*** (P < 0.001) for
lung tumour tissue (excluding samples 9 and 3) and rs = 0.651**
(P < 0.01) for normal tissue.
We measured the activity of the one-electron reducing enzyme
Cytb5R in paired tumour and normal tissues (Tables 3 and 5). We
found less heterogeneity in this enzyme activity than that detected
for DTD activity. In normal lung tissue, Cytb5R varied between 3
and 174 nmol min-1 mg-1 protein; patient 1 exhibited a very high
value (174 ± 2 nmol min-1 mg-' protein) and patients 10 and 11
showed a very low value (2.7 and 3.8 respectively); excluding
these values, the mean is 48.00 ± 4.85 nmol min-' mg-1 protein.
In the lung tumour tissue, the activity was in general lower;
it ranged between 3 and 56 nmol min-1 mg-1 protein (mean
30.42 ± 3.24 nmol min-1 mg-1 protein). The Mann-Whitney
U-rank sum test revealed significant differences between normal
and tumour tissue (P < 0.05). Normal breast tissueCytb5R activity
ranged between 0 and 69 nmol min-' mg-1 protein, while tumour
Cytb5R activity ranged between 8 and 42 nmol min-1 mg-1 protein
(Table 5). In 56% of the patients, Cytb5R in tumour tissue was
lower than in the normal tissue, but the difference between the
activities in the two types oftissue was not significant.
DISCUSSION
In the present work, we have distinguished two different behav-
iours conceming the two-electron reducing enzyme DTD. The
activity ofthis enzyme was induced significantly in tumour tissue
from 70% of the breast cancer patients and from 53% of the lung
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Figure 1 Western blot examples of human lung tissue S9 fractions (A
and B). Total protein (50 9g) was developed with polyclonal anti-rat DTD.
Lanes 1, 3 and 5 contain lung tumour tissue (T), and lanes 2, 4 and 6 contain
the corresponding normal tissue (N). Numbers before T or N indicate the
patient number. Lane 7, internal control (C), human lung cancer cell line
HTB-54 (50 gg). Lane 8, rat liver (RL) S9 fraction (50 ,ug)
cancer patients included in this study, confirming some previous
observations (Schlager and Powis, 1990; Smitskamp-Wilms et al,
1995). However, there were a considerable number of exceptions
to this behaviour: lung tumours from patients 12-19 and breast
tumours from patients 1 and 16-20 showed low DTD activity.
Studies on the regulation ofexpression of DTD (Prochaska and
Talalay, 1988; Cresteil and Jaiswal, 1991; Belinsky and Jaiswal,
1993) indicated that DTD can be induced by cytotoxic drugs. Four
patients in our study received prior chemotherapy, and there was
no evidence of induction of DTD levels in the tumours of treated
patients. In fact, three ofthem presented very low values (patients
18 and 19 from Table 3 and patient 20 from Table 5), and the other
patient presented levels that were not especially high (patient 5
from Table 3).
We could not find any difference between the tumour DTD
activity of subjects who were past smokers and subjects who were
active smokers, since patients who were current smokers (see
Table 1) presented a considerable increase in their tumour DTD
activity. Our data are in disagreement with those published previ-
ously. Schlager and Powis (1990) described the cigarette smoking
history of the subjects as a major cause of variability of DTD
activity. They found that lung tumours from non-smokers or past
smokers exhibited considerably higher DTD activity in compar-
ison with the corresponding normal tissue, but tumours from
smokers showed no increase in tumour DTD.
We found that several tumour characteristics correlated with
DTD tumour activity: grade, stage and histological type. DTD
activity seemed to be more induced in well-differentiated
tumours than in the moderately or poorly differentiated ones. It
also tended to be higher in tumours in stage I or II and in epider-
moid carcinomas.
A higher expression of DTD gene (NQO1 locus) in normal
tissue surrounding hepatic tumours in comparison with the normal
tissues from the same origin has been reported (Cresteil and
Jaiswal, 1991). This fact and other studies suggested that soluble
factor(s) from tumour cells could diffuse into the surrounding
normal tissues and activate the expression of NQO1 by an
unknown mechanism (Belinsky and Jaiswal, 1993). If this were
true, the high values of the enzyme, both activity and protein
expression in the normal tissue from some patients, could be
explained. Also, the possibility of tumoral infiltration cannot be
discarded.
There was an absence of correlation between DTD activity and
DTD expression in lung tumour samples 9 and 3. Other enzymes
B
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Figure 2 Western blot examples of human breast tissue S9 fractions
(A - C). Total protein (50 ,ug) was developed with a polyclonal anti-rat DTD
antibody. Tumour tissue (T), normal tissue (N) or peripheral tissue (P) are
preceded by the patient number. DTD, purified rat DTD protein (10 jg). C,
internal control, human lung cancer cell line HTB-54 (50 ig). RL, rat liver S9
fraction (50 jg). The approximate molecular weight of the band detected is
indicated
can use menadione as a substrate: carbonyl reductase and Cytb5R
are examples; and both of these can be inhibited by dicoumarol,
the DTD inhibitor (Wermuth, 1981; Hodnick and Sartorelli, 1993).
Therefore, it could be that other enzymes in the tumour tissue of
patient 9 contributed to the apparently elevated DTD activity. In
tumour tissue from patient 3, higher protein expression than
activity was measured. There is little information available on
substrate specificities of the different forms of NQOs; the NQO2-
encoded protein is 43 amino acids shorter at the carboxy terminal
end, and several authors have suggested distinct affinities of
diaphorases (NQOs) for the metabolism of several substrates,
including menadione (Edwards et al, 1980; Segura-Aguilar and
Lind, 1987). The NQO2 cDNA-encoded protein was found to be
50-fold to 100-fold less active at reducing the menadione readily
metabolized by NQOl protein (Jaiswal et al, 1990), so we cannot
discard the theory that patient 3 had this isoenzyme.
Regarding the one-electron reducing enzyme Cytb5R, we found
no important differences between normal and tumour tissues. The
levels ofactivity found in tumours were as much as 16 times lower
than those found for DTD, which is consistent with previous
results in lung tumour cell lines (Plumb et al, 1994b). The lack of
induction ofCytb5R makes it clear that different regulatory mech-
anisms are implicated in the expression of the two enzymes. In
consequence, these results do not encourage a therapeutic strategy
based on this reductase.
In our opinion, this study questions the expectations created
around the enzyme DTD. Although it is true that there are clear
differences of expression in tumour vs normal tissue in some
patients, it is also true that the level ofinduction is very heteroge-
neous and seldom tenfold higher. In several in vitro studies, a
significant correlation has been obtained between aerobic sensi-
tivity to E09 and DTD activity, but in these studies the range of
DTD activity among the different cell lines used was much higher
than that found in human tumours. This fact, together with the
high proportion ofexceptions encountered in the tumour tissue of
a number of patients, provides a note of caution. In short, DTD-
mediated chemotherapy should be indicated only for individual
patients with a demonstrated, very high level of activity of this
particular enzyme measured in tumour biopsy specimens.
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In summary, this article provides more data on bioreductive
enzyme levels found in clinical samples and encourages us to
study agreater number ofhuman tumours in order to determine the
true potential for therapeutic exploitation of DTD-dependent
bioreductive drugs.
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